Skip to content
OpenCapital
Get started

Gossamer Bio, Inc. GOSS Q1 2026 earnings

Reported May 18, 2026 · Before market open

Revenue$17.0MBeat by $12.3MDiluted EPS-$0.20Miss by $0.03
Revenue estimate$4.7M
EPS estimate-$0.17

Next report

Aug 4, 2026 (In 3 weeks)
Revenue estimate$4.3M
EPS estimate-$0.08

Versus estimates

Revenue

Q1 2026$17.0MBeat by $12.3M
Q4 2025$13.8MBeat by $6.3MQ3 2025$13.3MBeat by $5.8MQ2 2025$11.5MBeat by $6.1MQ1 2025$9.9MBeat by $5.9MQ4 2024$9.4MBeat by $2.5M

Diluted EPS

Q1 2026-$0.20Miss by $0.03
Q4 2025-$0.21Miss by $0.01Q3 2025-$0.21Miss by $0.02Q2 2025-$0.17Beat by $0.01Q1 2025-$0.16Beat by $0.02Q4 2024-$0.15Beat by $0.02

Ask the moment Gossamer Bio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Gossamer Bio, Inc. report Q1 2026 earnings?
Gossamer Bio, Inc. (GOSS) reported Q1 2026 earnings on May 18, 2026 before market open.
What were Gossamer Bio, Inc.'s Q1 2026 revenue and EPS?
Gossamer Bio, Inc. reported revenue of $17.0M and diluted EPS of $-0.20 for Q1 2026.
Did Gossamer Bio, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $4.7M by $12.3M. EPS missed the consensus estimate of $-0.17 by $0.03.
How did Gossamer Bio, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 71.5% from $9.9M a year earlier and diluted EPS declined 25.0% from $-0.16.
Where can I find Gossamer Bio, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001728117-26-000036) and the 10-Q periodic report (0001728117-26-000032) directly on SEC EDGAR. The filing index links above go to sec.gov.